CVS Health Co. (NYSE:CVS) Stock Holdings Lessened by Beacon Pointe Advisors LLC

Beacon Pointe Advisors LLC decreased its position in CVS Health Co. (NYSE:CVS - Free Report) by 46.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,978 shares of the pharmacy operator's stock after selling 17,091 shares during the quarter. Beacon Pointe Advisors LLC's holdings in CVS Health were worth $897,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CVS. Ridgewood Investments LLC increased its stake in CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after purchasing an additional 450 shares during the last quarter. Stonebridge Financial Group LLC bought a new stake in shares of CVS Health during the 4th quarter valued at about $28,000. Hopwood Financial Services Inc. acquired a new stake in CVS Health during the fourth quarter worth about $29,000. Financial Perspectives Inc lifted its holdings in CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after acquiring an additional 466 shares during the last quarter. Finally, MidAtlantic Capital Management Inc. boosted its stake in CVS Health by 112.1% in the fourth quarter. MidAtlantic Capital Management Inc. now owns 827 shares of the pharmacy operator's stock valued at $37,000 after acquiring an additional 437 shares during the period. 80.66% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CVS. Wolfe Research raised their price target on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Mizuho boosted their price target on shares of CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Barclays upped their price target on shares of CVS Health from $73.00 to $82.00 and gave the stock an "overweight" rating in a research report on Friday. UBS Group lifted their price objective on shares of CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a research report on Friday. Finally, JPMorgan Chase & Co. upped their target price on shares of CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 18th. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $74.81.

Insider Activity

In related news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael F. Mahoney bought 30,000 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by company insiders.

CVS Health Price Performance

CVS stock traded down $0.79 during trading hours on Tuesday, hitting $66.32. 6,984,481 shares of the stock traded hands, compared to its average volume of 11,487,462. The stock has a 50-day simple moving average of $66.79 and a 200 day simple moving average of $58.81. The company has a market cap of $83.61 billion, a P/E ratio of 18.12, a P/E/G ratio of 0.98 and a beta of 0.60. CVS Health Co. has a one year low of $43.56 and a one year high of $72.51. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The company had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. During the same quarter in the previous year, the company posted $1.31 EPS. The business's revenue was up 7.0% compared to the same quarter last year. Equities analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date was Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is presently 63.48%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.